Dr. Gregory Friedman of the University of Alabama at Birmingham (UAB) received a three-year, $750,000 R01 grant from the U.S. Food and Drug Administration (FDA) for a Phase I immunotherapy clinical trial of engineered cold-sore (or herpes) virus G207 for the treatment...